The FDA's own scientists have concluded that none of the seven peptides up for a compounding vote this month has enough evidence to be sold legally through pharmacies. Their verdict landed three weeks before the panel that will actually decide, and that panel is stacked with people who make money from peptides.
On July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee meets to vote ↗ on whether seven peptides belong on the 503A Bulk Drug Substances List. That list is the legal switch that lets a licensed compounding pharmacy make a drug for a named patient. Ahead of the meeting, FDA staff released briefing documents, and NBC News reported ↗ that the agency's reviewers recommend against adding any of the seven.
Day one covers BPC-157 ↗, KPV ↗, TB-500 ↗ and MOTS-c ↗. Day two covers emideltide ↗, the sleep peptide better known as DSIP, plus Semax ↗ and Epitalon ↗. The groups that nominated them pitched the set for wound healing, sleep, metabolism and longevity.
The most concrete finding is an absence
For TB-500 and KPV, both sold as wound healers, FDA scientists wrote that they could not find a single study in which the substance had been given to a human. Not a weak trial. None. Across the whole set, the reviewers pointed to missing human safety and efficacy data, signs of immune reactions (immunogenicity) in adverse-event reports, and peptide-related impurities, and said the potential for harm could not be ruled out.
That last point is not abstract. Independent testing of gray-market peptide vials, the kind sold online as "research use only," has turned up the toxic heavy metals arsenic and lead, in some cases at roughly ten times the limit allowed for an injectable drug.
Who gets to decide
What lifts this above a routine staff review is who votes on it. STAT News reported ↗ that of the fourteen members now seated on the committee, seven have ties to peptide businesses or clinics. Among the new appointees is Bobby Harshbarger, a Tennessee state senator and pharmacist at his family's compounding pharmacy, whose mother, Representative Diana Harshbarger, has urged Health Secretary Robert F. Kennedy Jr. to relax peptide rules. Another appointee runs a chain of men's-health clinics selling peptide injections. A third charges 500 dollars for peptide-and-hormone consultations.
The committee that will judge whether the evidence is sufficient is populated, in part, by people whose businesses depend on the answer being yes.
The split is the story
In February, Kennedy publicly pushed to expand access to exactly these peptides. His own agency's scientists have now put the opposite conclusion in writing. The July 23 meeting is where those two positions collide.
A recommendation against listing does not ban anything overnight. It keeps these peptides where they already are, outside the pharmacy system, moving through vendors that stamp vials "research use only" to stay outside the rules that govern medicines. What it does is put the FDA's scientific position on the record and raise the cost of a vote that overrides it. If a panel loaded with peptide sellers votes to add molecules the agency's own reviewers say have no human data behind them, that gap becomes the headline.
peptidemodel hosts a card for all seven, from BPC-157 ↗ to Epitalon ↗, each carrying the evidence grade the platform assigns from the published literature. The agency's review and the platform's grading are circling the same fact from different directions. The peptides with the loudest gray-market followings are, on the data, the thinnest.